- Generic name
- Levetiracetam
- Strength
- 500 mg/5 ml
- Dosage form
- Injection
- Manufactured by
- Opsonin Pharma Limited
Levefix 500 Injection
About Levefix 500 500 mg/5 ml Injection
Levefix 500 is a injection from Opsonin Pharma Limited, with the generic name Levetiracetam. Levefix 500 is used for partial-onset seizures, a type of epilepsy where fits start in one part of the brain.
There are 34 brands of Levetiracetam listed in Bangladesh. The lowest listed price is Citazar 250 mg Tablet at ৳ 15.11 per unit.
What is Levefix 500 500 mg/5 ml Injection?
Levefix 500 comes as a injection with 500 mg/5 ml of Levetiracetam, from Opsonin Pharma Limited. It contains Levetiracetam, which belongs to a group of medicines called anti-epileptics. It contains Levetiracetam 500 mg/5 ml, a medicine from the anti-epileptic group. Whether it suits you is a decision for your doctor.
Uses of Levefix 500
Levefix 500 is used for partial-onset seizures, a type of epilepsy where fits start in one part of the brain. It may be prescribed as an add-on therapy with other anti-epileptic medicines, or as monotherapy in certain patients. Doctors may prescribe it as the only epilepsy medicine for some adults and adolescents with newly diagnosed epilepsy, or as an add-on treatment for other age groups. Your doctor will decide whether it is suitable for you.
How to use Levefix 500
Do not attempt to inject it yourself. Levefix 500 is given as an injection by a healthcare professional. Do not inject it yourself unless a doctor has shown you how. Take Levefix 500 injection exactly as your doctor tells you. The doctor decides the dose, how often it is given, and for how long, based on the person's condition and response. Do not change the dose or stop early without asking your doctor.
Side effects of Levefix 500
Get medical help promptly if you notice unusual bruising or bleeding, signs of infection such as fever, or a severe reaction, as these need to be checked. Tell the doctor or pharmacist if any side effect bothers you or does not settle, and seek medical help promptly for anything severe or unexpected. Like all medicines, Levefix 500 injection can cause side effects, although not everyone gets them.
Safety and precautions
Levetiracetam is not recommended in pregnancy or in women who could become pregnant and are not using contraception, unless the doctor considers it necessary. It passes into breast milk, so breastfeeding is not recommended unless the doctor decides the benefit outweighs the risk. Always ask the doctor first about any concerns. Tell your doctor about all the other medicines you take.
Frequently asked questions
What does Levefix 500 treat?
Levefix 500 is used for partial-onset seizures, a type of epilepsy where fits start in one part of the brain. It may be prescribed as an add-on therapy with other anti-epileptic medicines, or as monotherapy in certain patients.
How is Levefix 500 used?
Do not attempt to inject it yourself. Levefix 500 is given as an injection by a healthcare professional.
Can Levefix 500 cause side effects?
Get medical help promptly if you notice unusual bruising or bleeding, signs of infection such as fever, or a severe reaction, as these need to be checked. Tell the doctor or pharmacist if any side effect bothers you or does not settle, and seek medical help promptly for anything severe or unexpected.
Is Levefix 500 safe for everyone?
Levetiracetam is not recommended in pregnancy or in women who could become pregnant and are not using contraception, unless the doctor considers it necessary. It passes into breast milk, so breastfeeding is not recommended unless the doctor decides the benefit outweighs the risk.
Indications
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy. ... Read more
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
- in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
Dosage & Administration
Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more: The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decrease every two to four weeks.
Pediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases, oral solution should be used.
- Monotherapy: The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.
- Add-on therapy: Oral solution is the preferred formulation for use in infants and children under the age of 6 years. For children 6 years and above, oral solution should be used for doses under 250 mg, for doses not in multiples of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. The lowest effective dose should be used. The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily. Dosing for children 50 kg or greater is the same as in adults.
- Add-on therapy: For infants aged from 1 month to less than 6 months: The oral solution is the formulation to use in infants.
Interaction
Probenecid: Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.
Methotrexate: Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.
Laxatives: There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.
Food and alcohol: The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced. No data on the interaction of levetiracetam with alcohol are available.
Contraindications
Side Effects
- Adult patients: somnolence, asthenia, infection and dizziness
- Pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability
Pregnancy & Lactation
Precautions & Warnings
Acute kidney injury: The use of levetiracetam has been very rarely associated with acute kidney injury with a time to onset ranging from a few days to several months.
Blood cell counts: Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders.
Suicide: Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known. Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.
Paediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Available data in children did not suggest an impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.
Overdose Effects
Storage Conditions
Alternative brands of Levetiracetam
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.